Table 1

Baseline patient characteristics of analysed patient groups

Patients treated with RTXControl groupRA (SF analysis*)OA (SF analysis)
 No. of patients50146724
 Female, no. (%)36 (72)7 (50)49 (73)15 (63)
 Age, median (range), years58 (22–84)45 (23–73)61 (26–80)62 (44–83)
Disease status
 D(sease duration, median (range), years12 (1–50)19 (2–55)5 (2–34)
 ESR, mean (±SD) mm/h43.7 (±27.0)50.8 (±40.7)NA
 CRP, mean (±SD) mg/litre35.2 (±30.2)47.8 (±65.3)NA
 DAS28, mean (±SD)6.5 (±1.1)NANA
 RF+ (%)41 (82)41 (61)
 IgM-RF, mean (±SD) IU/ml205.1 (±310.6)NANA
 IgG-ACPA, mean (±SD) IU/ml1172 (±2268)NANA
 Number of previous DMARDs, median (range)5 (2–10)NA
 Number of previous biological agents, median (range)2 (0–4)NA
 Biologicals (aTNF n=9, Anak n=1, RTX n=5)9 (13)
 Methotrexate, n (%)41 (82)29 (43)
 Methotrexate dosage, median (range) mg/week15 (5–30)NA
 Other DMARDs (HChl n=6, Sul n=2, Lef n=6, Aur n=1)17 (20)
 No DMARDs9 (10)
 Corticosteroids, n (%)34 (68)23 (34)
 Prednisone dosage, median (range) mg/day10 (5–15)NA
  • * Average (±SD) age, disease duration, ESR and CRP of these 12 patients were 57.2 (9.4), 16.2 (15.9), 29.8 (24.6) and 17.8 (8.8), respectively.

  • Paired samples of synovial fluid and serum were analysed from 12 patients.

  • ACPA, anti-citrullinated protein antibody; aTNF, anti-TNF; Anak, anakinra; Aur, auromyose; CRP, C reactive protein; DAS28, disease activity score based on 28 joints; DMARDs, disease-modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate; HChl, hydroxychloroquine; Lef, leflunomide; NA, not available; OA, osteoarthritis; RA, rheumatoid arthritis; RF, rheumatoid factor; RTX, rituximab; Sal, salazosporine; Sul, sulfasalazine; TNF, tumour necrosis factor.